A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat

NCT04150289 | Completed

• 1 other identifier: 20192475
• Study Type: observational
• Target: 248
• Locations: 1 country
• Sites: 7

Brief Summary

This study aims to describe current treatment patterns in the real-world setting among patients with multiple myeloma who are initiating treatment with (or changing treatment to) panobinostat and explore the associations with baseline patient characteristics, healthcare resource utilization, and clinical outcomes.

Conditions

Multiple Myeloma

Keywords

Farydak; panobinostat

Outcome Measures

Primary Outcomes (1)

• Response to treatment

  Looking for patient reproted response to treatment with panobinostat

  24 months

Interventions

Farydak DRUG

non-interventional study

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population will be any adult who is clinically diagnosed with multiple myeloma who is actively taking panobinostat.

You may qualify if:

• Willing and able to provide written informed consent
• At least 18 years of age
• Clinical diagnosis of multiple myeloma that meets published diagnostic criteria
• Initiating panobinostat within 60 days of enrollment
• ECOG performance status 0-1
• Availability of documentation from the patient's medical records regarding previous myeloma treatment, response, and duration of response
• Willing and able to complete the PRO questionnaire

You may not qualify if:

• Diagnosed with any B-cell malignancy other than myeloma
• Estimated life expectancy \<6 months
• Currently enrolled in any interventional clinical trial at study entry (note: patients who enroll in an interventional clinical trial after enrollment may remain in the registry)

Sponsors & Collaborators

• pharmaand GmbH: lead

Study Sites (7)

American Health Network Indiana

Indianapolis, Indiana, 46260, United States

Location

Southern Nevada Cancer Research Foundation and Optum Cancer Care

Las Vegas, Nevada, 89106, United States

Location

Oncology Specialists of Charlotte

Charlotte, North Carolina, 28204, United States

Location

Southern Oncology Specialists

Huntersville, North Carolina, 28078, United States

Location

Gettysburg Cancer Center

Gettysburg, Pennsylvania, 17325, United States

Location

Coastal Cancer Center

Myrtle Beach, South Carolina, 29572, United States

Location

Carolina Blood and Cancer Care Associates

Rock Hill, South Carolina, 29732, United States

Location

MeSH Terms

Conditions

Multiple Myeloma

Interventions

Panobinostat

Condition Hierarchy (Ancestors)

Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases

Intervention Hierarchy (Ancestors)

Hydroxamic Acids; Hydroxylamines; Amines; Organic Chemicals; Hydroxy Acids; Carboxylic Acids; Indoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Study Design

• Study Type: observational
• Observational Model: ECOLOGIC OR COMMUNITY
• Time Perspective: PROSPECTIVE
• Target Duration: 24 Months
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 31, 2019
• First Posted: November 4, 2019
• Study Start: November 4, 2019
• Primary Completion: March 30, 2022
• Study Completion: March 30, 2022
• Last Updated: June 15, 2023

Record last verified: 2023-06

Data Sharing

• IPD Sharing: Will not share

Locations

US (7)